Related Experiment Video
Updated: Jan 5, 2026

Differentiation of a Human Neural Stem Cell Line on Three Dimensional Cultures, Analysis of MicroRNA and Putative Target Genes
Published on: April 12, 2015
Silencing CASC11 curbs neonatal neuroblastoma progression through modulating microRNA-676-3p/nucleolar protein 4 like
Zekun Yu1, Jing Zhang1, Jun Han2
1Department of Neonatology, the First Hospital of Jilin University, No. 71, XinMin Street, Changchun, 130021, Jilin, China.
Background:
Neuroblastoma is the commonest extracranial solid cancer for neonates. Long non-coding RNA cancer susceptibility 11 (CASC11) is corroborated as carcinogen in several tumors. But its role in neonatal neuroblastoma is poorly defined.
Methods:
Expression levels of CASC11, miR-676-3p, and NOL4L mRNA were analyzed by qRT-PCR in cells and tissues. Kaplan-Meier analysis was used to measure and analyze the survival time of patients with high/low CASC11. Neonatal neuroblastoma cell proliferation was reflected through colony-formation assay and CCK-8. Transwell assay was designed for detection of migratory and invasive capacities of neonatal neuroblastoma cells. Wound-healing assay was used for monitoring neuroblastoma cell migration. RNA pull-down, luciferase reporter, and RIP assays were utilized to identify the relationship between CASC11, miR-676-3p, and NOL4L on the basis of bioinformatics tools.
Results:
Highly expressed CASC11 was observed in neonatal neuroblastoma tissues and cells. High level of CASC11 indicated unsatisfactory survival of neonatal neuroblastoma patients. CASC11 depletion inhibited cell proliferation and invasiveness. CASC11 was a molecular sponge to release NOL4L from miR-676-3p inhibition in tumor cells. Upregulation of NOL4L abated the suppressed cell proliferation and invasiveness due to CASC11 downregulation.
Conclusion:
CASC11 sequestered miR-676-3p from NOL4L to facilitate neonatal neuroblastoma progression, hinting a CASC11-mediated therapeutic target for neonatal neuroblastoma.
Insights
Long non-coding RNA CASC11 promotes neonatal neuroblastoma by sequestering miR-676-3p, inhibiting NOL4L. Targeting CASC11 offers a potential therapeutic strategy for this cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Neuroblastoma is the most common extracranial solid cancer in neonates.
- Long non-coding RNA cancer susceptibility 11 (CASC11) is implicated in various cancers, but its role in neonatal neuroblastoma is unclear.
Purpose of the Study:
- To investigate the role of CASC11 in neonatal neuroblastoma.
- To elucidate the molecular mechanism of CASC11 in regulating neonatal neuroblastoma progression.
Main Methods:
- Quantitative real-time PCR (qRT-PCR) for gene expression analysis.
- Cell proliferation, migration, and invasion assays (colony-formation, CCK-8, Transwell, wound-healing).
- Molecular interaction studies including RNA pull-down, luciferase reporter, and RIP assays.
Main Results:
- CASC11 expression is significantly upregulated in neonatal neuroblastoma tissues and cells.
- High CASC11 levels correlate with poor patient survival.
- CASC11 depletion inhibits proliferation and invasiveness; CASC11 acts as a molecular sponge, releasing NOL4L from miR-676-3p inhibition.
Conclusions:
- CASC11 promotes neonatal neuroblastoma progression by sequestering miR-676-3p and upregulating NOL4L.
- CASC11 represents a potential therapeutic target for neonatal neuroblastoma.
More Related Videos
Related Concept Videos
MicroRNAs
MicroRNAs
Experimental RNAi
Abnormal Proliferation

